Spark Therapeutics Trial Terminated

As reported on the Investor Village site, the Spark trial, NCT01620801 has a terminated status.

After (Updated 2016_12_18)
1	<clinical_study> <study_id> <org_full_name> Spark Therapeutics </org_full_name> <org_study_id> AAV8-hFIX19-101 </org_study_id> <nct_id> NCT01620801 </nct_id> </study_id> <is_fda_regulated> Yes </is_fda_regulated> <is_section_801> Yes </is_section_801> <delayed_posting> No </delayed_posting> <brief_title> <textblock> Hemophilia B Gene Therapy - Spark </textblock> </brief_title> <official_title> <textblock> A Phase 1 Safety Study in Subjects With Severe Hemophilia B (Factor IX Deficiency) Using a Single-Stranded, Adeno-Associated Pseudotype 8 Viral Vector to Deliver the Gene for Human Factor IX </textblock> </official_title> <study_sponsor> <lead_sponsor> <agency> Spark Therapeutics </agency> </lead_sponsor> <sponsor> <agency> Children&apos;s Hospital of Philadelphia </agency> </sponsor> <sponsor> <agency> University of Pittsburgh </agency> </sponsor> <sponsor> <agency> Royal Prince Alfred Hospital, Sydney, Australia </agency> </sponsor> <sponsor> <agency> St. James&apos;s Hospital, Ireland </agency> </sponsor> </study_sponsor> <resp_party> <resp_party_type> Sponsor </resp_party_type> </resp_party> <oversight_info> <regulatory_authority> United States: Food and Drug Administration </regulatory_authority> <regulatory_authority> United States: NIH Office of Biotechnology Activities </regulatory_authority> <regulatory_authority> Australia: Therapeutic Goods Administration </regulatory_authority> <has_dmc> Yes </has_dmc> </oversight_info> <brief_summary> <textblock> Hemophilia B is a bleeding disease in males due to very low levels of coagulation factor IX (FIX) in the blood. The current treatment is intravenous injection of FIX clotting factor concentrates, in response to bleeding. This study will focus on the severe, most common type of hemophilia B. This study plans to use a virus called adeno-associated virus (AAV), which in nature causes no disease, and can be engineered to deliver the human FIX gene (AAV8-hFIX19 vector) to liver cells, where FIX is normally made. This study will use the AAV8-hFIX19 vector. </textblock> </brief_summary> <detailed_descr> <textblock> Hemophilia B is a bleeding disease in males due to very low levels of coagulation factor IX (FIX) in the blood. The major effect on health is joint disease caused by repeated bleeds into joints like the knee, hip, ankles and elbows. Rarely, the disease causes death due to bleeding into the brain or other important organs. The current treatment is intravenous injection of FIX clotting factor concentrates, in response to bleeding. This study will focus on the severe, most common type of hemophilia B. This study plans to use a virus called adeno-associated virus (AAV), which in nature causes no disease, and can be engineered to deliver the human FIX gene (AAV8-hFIX19 vector) to liver cells, where FIX is normally made. Medical researchers in the United States and England have recently used an AAV vector similar to the one planned for this study, and found that after a single intravenous injection of the vector, blood levels of FIX reached levels greater than 1%, high enough to change the course of disease from severe to moderate. This means that the need to take FIX clotting factor concentrates has decreased, or even stopped. While these are important results, it needs to be noted that two of the six subjects who received the vector at higher doses developed inflammation of the liver. These subjects were treated with a steroid medication called Prednisolone, which is commonly used for serious types of inflammation. Prednisolone seemed to decrease the liver inflammation, as measured by a decrease in blood levels of elevated liver enzymes, and stability of FIX levels at greater than 1% of normal. This study will use the AAV8-hFIX19 vector. The vector will be injected once into a peripheral vein of each subject, while the subject is in the hospital. If everything is fine, the subject will be discharged from the hospital the next day. Three doses of vector (low, middle, and high) will be tested in up to 15 different subjects, depending on safety outcome (as determined by blood and urine tests) and results of FIX levels. If some subjects develop liver inflammation, a short, tapering course of corticosteroids will be used. </textblock> </detailed_descr> <status_block> <status>	<clinical_study> <study_id> <org_full_name> Spark Therapeutics </org_full_name> <org_study_id> AAV8-hFIX19-101 </org_study_id> <nct_id> NCT01620801 </nct_id> </study_id> <is_fda_regulated> Yes </is_fda_regulated> <is_section_801> Yes </is_section_801> <delayed_posting> No </delayed_posting> <brief_title> <textblock> Hemophilia B Gene Therapy - Spark </textblock> </brief_title> <official_title> <textblock> A Phase 1 Safety Study in Subjects With Severe Hemophilia B (Factor IX Deficiency) Using a Single-Stranded, Adeno-Associated Pseudotype 8 Viral Vector to Deliver the Gene for Human Factor IX </textblock> </official_title> <study_sponsor> <lead_sponsor> <agency> Spark Therapeutics </agency> </lead_sponsor> <sponsor> <agency> Children&apos;s Hospital of Philadelphia </agency> </sponsor> <sponsor> <agency> University of Pittsburgh </agency> </sponsor> <sponsor> <agency> Royal Prince Alfred Hospital, Sydney, Australia </agency> </sponsor> <sponsor> <agency> St. James&apos;s Hospital, Ireland </agency> </sponsor> </study_sponsor> <resp_party> <resp_party_type> Sponsor </resp_party_type> </resp_party> <oversight_info> <regulatory_authority> United States: Food and Drug Administration </regulatory_authority> <regulatory_authority> United States: NIH Office of Biotechnology Activities </regulatory_authority> <regulatory_authority> Australia: Therapeutic Goods Administration </regulatory_authority> <has_dmc> Yes </has_dmc> </oversight_info> <brief_summary> <textblock> Hemophilia B is a bleeding disease in males due to very low levels of coagulation factor IX (FIX) in the blood. The current treatment is intravenous injection of FIX clotting factor concentrates, in response to bleeding. This study will focus on the severe, most common type of hemophilia B. This study plans to use a virus called adeno-associated virus (AAV), which in nature causes no disease, and can be engineered to deliver the human FIX gene (AAV8-hFIX19 vector) to liver cells, where FIX is normally made. This study will use the AAV8-hFIX19 vector. </textblock> </brief_summary> <detailed_descr> <textblock> Hemophilia B is a bleeding disease in males due to very low levels of coagulation factor IX (FIX) in the blood. The major effect on health is joint disease caused by repeated bleeds into joints like the knee, hip, ankles and elbows. Rarely, the disease causes death due to bleeding into the brain or other important organs. The current treatment is intravenous injection of FIX clotting factor concentrates, in response to bleeding. This study will focus on the severe, most common type of hemophilia B. This study plans to use a virus called adeno-associated virus (AAV), which in nature causes no disease, and can be engineered to deliver the human FIX gene (AAV8-hFIX19 vector) to liver cells, where FIX is normally made. Medical researchers in the United States and England have recently used an AAV vector similar to the one planned for this study, and found that after a single intravenous injection of the vector, blood levels of FIX reached levels greater than 1%, high enough to change the course of disease from severe to moderate. This means that the need to take FIX clotting factor concentrates has decreased, or even stopped. While these are important results, it needs to be noted that two of the six subjects who received the vector at higher doses developed inflammation of the liver. These subjects were treated with a steroid medication called Prednisolone, which is commonly used for serious types of inflammation. Prednisolone seemed to decrease the liver inflammation, as measured by a decrease in blood levels of elevated liver enzymes, and stability of FIX levels at greater than 1% of normal. This study will use the AAV8-hFIX19 vector. The vector will be injected once into a peripheral vein of each subject, while the subject is in the hospital. If everything is fine, the subject will be discharged from the hospital the next day. Three doses of vector (low, middle, and high) will be tested in up to 15 different subjects, depending on safety outcome (as determined by blood and urine tests) and results of FIX levels. If some subjects develop liver inflammation, a short, tapering course of corticosteroids will be used. </textblock> </detailed_descr> <status_block> <status>
2	Active, not recruiting	Terminated